United Therapeutics Co. (NASDAQ:UTHR) EVP Sells $3,367,980.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now owns 36,781 shares of the company’s stock, valued at approximately $11,261,606.58. The trade was a 23.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

United Therapeutics Stock Down 4.1 %

Shares of UTHR stock opened at $279.69 on Wednesday. The firm has a market capitalization of $12.56 billion, a P/E ratio of 12.28, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a twelve month low of $230.39 and a twelve month high of $417.82. The stock’s fifty day simple moving average is $328.54 and its 200 day simple moving average is $353.09.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter in the prior year, the firm posted $4.36 earnings per share. As a group, equities research analysts expect that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently modified their holdings of the business. Newbridge Financial Services Group Inc. acquired a new stake in United Therapeutics in the fourth quarter valued at $25,000. Dunhill Financial LLC increased its stake in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 50 shares during the period. State of Wyoming bought a new position in shares of United Therapeutics during the fourth quarter worth about $62,000. Millstone Evans Group LLC acquired a new position in shares of United Therapeutics in the fourth quarter worth approximately $67,000. Finally, MassMutual Private Wealth & Trust FSB boosted its holdings in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on UTHR. HC Wainwright reaffirmed a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.